DNB // Back Bay Industry & Venture Session
—Building on Nordic Healthcare’s Strong Foundations
In Auditorium 1
Explore the full agenda
The Nordics have built durable strengths: world-class science, disciplined operators, committed capital, and strong public partnerships. This session focuses on amplifying what already works. We’ll bring together founders, specialist investors, and policy shapers to turn these shared strengths into concrete next-step commitments - across capital formation, talent development, and data access.
You’ll hear directly from specialist investors about what they truly need and how to encourage more of them to engage in the Nordic region.
Expect fast-paced, candid conversations that translate frameworks into action for the next 12 months: what to prioritize, who funds it, how to execute global ambitions, and how to measure progress.
Healthcare Investment Access program (HIA)
We’ll also announce the eight new companies joining the HIA cohort—representing the best and brightest of Nordic healthcare, with the potential to become the next generation of success stories in the region.
Watch them pitch live in the Lions’ Den to international investors.
-
Norway Growth Company Spotlight
This year, we are showcasing six early-stage companies identified as tomorrow’s winners. Together, these companies represent a broad range of segment diversification within healthcare innovations in Norway. With products and solutions addressing areas of high unmet medical need, we look forward to sharing their journey so far and highlighting the key milestones they aim to achieve in the near term.
Keynote speakers:
Emanuele is the founding CEO of ARTBIO – he worked closely with Roy Larsen and our investors to build the company and its business model.
Previously, he was Head of Europe for Cell and Gene Therapies at Novartis Oncology, where he oversaw all commercialization aspects of Kymriah in Europe, the first FDA approved CAR-T cell therapy. Emanuele was with Novartis since 2012 in various executive roles in Sandoz where he worked globally, in Eastern Europe, and in Romania.
Previously he held positions at Nano Terra, McKinsey & Co., and Surface Logix. Emanuele was the co-founder of Enumeral Biomedical and served on its board of directors through its public listing in 2014.
He served on the SAB of Anixa Biosciences and currently serves on the SAB of Elicio Therapeutics.
Emanuele earned a Ph.D. in Physical Chemistry from Harvard University and bachelor's and master's degrees in Chemistry from Georgetown University.
Kari E. Krogstad is President & CEO of Medistim ASA, a global leader in ultrasound-based solutions for cardiac, vascular, and transplant surgery.
Since joining the company in 2009, she has guided Medistim through significant international growth and a strengthened focus on innovation and clinical outcomes. With more than three decades of experience in the life sciences and MedTech sectors, Kari has held senior commercial leadership and board positions across biotechnology, diagnostics and healthcare technology companies. Combining deep industry knowledge with strategic vision, she continues to drive Medistim’s global expansion and commitment to improving surgical quality.
She holds qualifications in biotechnology and business leadership, and serves on several boards, including Gentian Diagnostics, Vistin Pharma and NordicNeuroLab.
